Preclinical study of Ublituximab, a Glycoengineered anti-human CD20 antibody, in murine models of primary cerebral and intraocular B-cell lymphomas.

Investigative ophthalmology & visual science

Volumn 54, Issue 5, 2013, Pages 3657-3665

  Ben Abdelwahed, Rym ^a   Donnou, Sabrina ^a   Ouakrim, Hanane ^a   Crozet, Lucile ^a   Cosette, Jérémie ^a   Jacquet, Alexandra ^a   Tourais, Isabel ^a   Fournès, Bénédicte ^a   Gillard Bocquet, Mélanie ^a   Miloudi, Amine ^a   Touitou, Valérie ^a   Daussy, Cécile ^a   Naud, Marie Christine ^a   Fridman, Wolf Herman ^a   Sautès Fridman, Catherine ^a   Urbain, Rémi ^a   Fisson, Sylvain ^a  

^a not available ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD20 ANTIGEN; MONOCLONAL ANTIBODY; RITUXIMAB; UBLITUXIMAB;

ANIMAL; ARTICLE; B CELL LYMPHOMA; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CENTRAL NERVOUS SYSTEM TUMOR; COMPARATIVE STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG SCREENING; EYE TUMOR; FEMALE; GLYCOENGINEERED MONOCLONAL ANTIBODY; HUMAN; HUMAN CD20; IMMUNOLOGY; MOUSE; PRIMARY INTRACEREBRAL B CELL LYMPHOMA (PCL); PRIMARY INTRAOCULAR B CELL LYMPHOMA (PIOL); PRIMARY VITREORETINAL LYMPHOMA (PVRL); PROTEIN ENGINEERING; TUMOR CELL LINE;

GLYCOENGINEERED MONOCLONAL ANTIBODY; HUMAN CD20; PRIMARY INTRACEREBRAL B CELL LYMPHOMA (PCL); PRIMARY INTRAOCULAR B CELL LYMPHOMA (PIOL); PRIMARY VITREORETINAL LYMPHOMA (PVRL); UBLITUXIMAB;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CENTRAL NERVOUS SYSTEM NEOPLASMS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EYE NEOPLASMS; FEMALE; HUMANS; LYMPHOMA, B-CELL; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; PROTEIN ENGINEERING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84883589236     PISSN: None     EISSN: 15525783     Source Type: None    
DOI: 10.1167/iovs.12-10316     Document Type: Article

References (0)